Article
Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jul 2016
Chen Yen-Fu, Hsieh Min-Shu, Wu Shang-Gin, Chang Yih-Leong, Yu Chong-Jen, Yang James Chih-Hsin, Yang Pan-Chyr, Shih Jin-Yuan
Abstract excerpt
INTRODUCTION: The efficacy of pemetrexed-based chemotherapy in patients with advanced lung adenocarcinoma with novel ROS proto-oncogene 1, receptor tyrosine kinase gene (ROS1) oncogenic rearrangement is unclear. This study aimed to compare the efficacy of pemetrexed-based chemotherapy in patients with advanced ROS1-fusion lung adenocarcinoma with its efficacy in those having different driver mutations. METHODS:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.